Cost-effectiveness of somatrogon in the Spanish pediatric population with growth hormone deficiency

References

• Cheetham T, Davies JH. Investigation and management of short stature. Arch Dis Child. 2014;99(8):767–771. doi: 10.1136/archdischild-2013-304829
   PubMed Web of Science ®Google Scholar
• López JP, Ariza AB. Talla baja de etiología no determinada y cada vez menos idiopática. Rev Esp Endocrinol Pediatr. 2021;12:21–34.
   Google Scholar
• Cohen LE. Idiopathic short stature: a clinical review. JAMA. 2014;311(17):1787–1796. doi: 10.1001/jama.2014.3970
   PubMed Web of Science ®Google Scholar
• Murray PG, Clayton PE, Chernausek SD. A genetic approach to evaluation of short stature of undetermined cause. Lancet Diabetes Endocrinol. 2018;6(7):564–574. doi: 10.1016/S2213-8587(18)30034-2
   PubMed Web of Science ®Google Scholar
• Lindsay R, Feldkamp M, Harris D, et al. Utah growth study: growth standards and the prevalence of growth hormone deficiency. J Pediatr. 1994;125(1):29–35. doi: 10.1016/S0022-3476(94)70117-2
   PubMed Web of Science ®Google Scholar
• Vimpani GV, Vimpani AF, Lidgard GP, et al. Prevalence of severe growth hormone deficiency. Br Med J. 1977;2(6084):427–430. doi: 10.1136/bmj.2.6084.427
   PubMed Web of Science ®Google Scholar
• Thomas M, Massa G, Craen M, et al. Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986-2001. Eur J Endocrinol. 2004;151:67–72. doi: 10.1530/eje.0.1510067
   PubMed Web of Science ®Google Scholar
• Donoso MA, Díaz S, Oyagüez I, et al. Impacto presupuestario de la utilización de hormona de crecimiento de la edad pediátrica a la adulta. Farm Hosp. 2012;36:3–10. doi: 10.1016/j.farma.2010.11.004
   PubMedGoogle Scholar
• Luzuriaga Tomás C, Oyarzabal Irigoyen M, Caveda Cepas E, et al. el grupo de investigadores españoles del estudio GeNeSIS. Seguridad y efectividad del tratamiento con hormona de crecimiento: estudio GeNeSIS en España. An Pediatr (Barc). 2016;84:139–147. doi: 10.1016/j.anpedi.2015.05.002
   PubMedGoogle Scholar
• Grimberg A, DiVall SA, Polychronakos C, et al. Drug and therapeutics committee and ethics committee of the pediatric endocrine society. guidelines for growth hormone and insulin-like growth factor-i treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2016;86(6):361–397. doi: 10.1159/000452150
   PubMed Web of Science ®Google Scholar
• Fisher BG, Acerini CL. Understanding the growth hormone therapy adherence paradigm: a systematic review. Horm Res Paediatr. 2013;79(4):189–196. doi: 10.1159/000350251
   PubMed Web of Science ®Google Scholar
• Rivolo S, Loftus J, Peter B, et al. Cost-effectiveness and cost-utility analysis of somatrogon once-weekly Injectable vs. Daily growth hormones for treating pediatric growth hormone deficiency (EE27). ISPOR Annual Meeting; Vienna, Austria: p. 6–9 Nov 2022. Available at: https://www.ispor.org/docs/default-source/euro2022/eva-27336-10-ispor-eu-a0-poster18oct22print-pdf.pdf?sfvrsn=79291a96_0 (access: 21 Nov 2022).
   Google Scholar
• Mohseni S, Heydari Z, Qorbani M, et al. Adherence to growth hormone therapy in children and its potential barriers. J Pediatr Endocrinol Metab. 2018;31(1):13–20. doi: 10.1515/jpem-2017-0157
   PubMed Web of Science ®Google Scholar
• Kapoor RR, Burke SA, Sparrow SE, et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child. 2008;93(2):147–148. doi: 10.1136/adc.2006.114249
   PubMed Web of Science ®Google Scholar
• Maggio MC, Vergara B, Porcelli P, et al. Improvement of treatment adherence with growth hormone by easypod™ device: experience of an Italian centre. Ital J Pediatr. 2018; 44(1):113. doi: 10.1186/s13052-018-0548-z
   PubMedGoogle Scholar
• Rodríguez Arnao MD, Rodríguez Sánchez A, Díez López I, et al. Adherence and long-term outcomes of growth hormone therapy with easypod™ in pediatric subjects: Spanish ECOS study. Endocr Connect. 2019;8:1240–1249.
   PubMed Web of Science ®Google Scholar
• Deal CL, Steelman J, Vlachopapadopoulou E, et al. Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a Phase 3 study. J Clin Endocrinol Metab. 2022;107(7):e2717–28. doi: 10.1210/clinem/dgac220
   PubMed Web of Science ®Google Scholar
• Maniatis AK, Carakushansky M, Galcheva S, et al. Treatment Burden of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a randomized study. J Endocr Soc. 2022;6(10):bvac117. doi: 10.1210/jendso/bvac117
   PubMed Web of Science ®Google Scholar
• Loftus J, Chen Y, Alvir JMJ, et al. Suboptimal adherence to daily growth hormone in a US real-world study: an unmet need in the treatment of pediatric growth hormone deficiency. Curr Med Res Opin. 2021;37(12):2141–2150. doi: 10.1080/03007995.2021.1982682
   PubMed Web of Science ®Google Scholar
• Ngenla 24 y 60 mg solución inyectable en pluma precargada. Ficha técnica o Resumen de características del producto. Available at: https://www.ema.europa.eu/en/documents/product-information/ngenla-epar-product-information_es.pdf (access: 14 Apr 2023).
   Google Scholar
• Orden SCB/953/2019, de 13 de septiembre, por la que se procede a la actualización en 2019 del sistema de precios de referencia de medicamentos en el Sistema Nacional de Salud. BOE Nº. 2019 de;225(19):101906.
   Google Scholar
• Acuerdo de 18 de diciembre de 2020, del consejo de administración del ente público Osakidetza, por el que se aprueban las tarifas por prestación de servicios sanitarios y docentes a terceros obligados al pago durante el ejercicio 2021. Available at: https://www.euskadi.eus/contenidos/informacion/osk_servic_para_empresas/es_def/adjuntos/LIBRO_DE_TARIFAS_2021_CAS_Firmado.pdf (access: 7 Dec 2021).
   Google Scholar
• NICE. Human growth hormone (somatropin) for the treatment of growth failure in children technology appraisal guidance [TA188]. Published: 26 May 2010. Available at: https://www.nice.org.uk/guidance/ta188 (access: 07 Dec 2021).
   Google Scholar
• Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ. 2011;12(3):219–230. doi: 10.1007/s10198-010-0224-8
   PubMed Web of Science ®Google Scholar
• Ranke MB, Lindberg A. KIGS International Board. Height at start, first-year growth response and cause of shortness at birth are major determinants of adult height outcomes of short children born small for gestational age and Silver-Russell syndrome treated with growth hormone: analysis of data from KIGS. Horm Res Paediatr. 2010;74(4):259–266. doi: 10.1159/000289570
   PubMed Web of Science ®Google Scholar
• Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children. ClinicalTrials.Gov identifier: NCT02968004. Available at: https://clinicaltrials.gov/ct2/show/NCT02968004?term=NCT02968004&rank=1 (access: 27 Apr 2022).
   Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford (UK): Oxford University Press; 2006.
   Google Scholar
• Rubio-Terrés C, Rubio-Rodríguez D. Probabilistic analysis: sensitivity analysis or main result? (Editorial). Pharmacoecon Open Acc. 2016;1:2. doi: 10.4172/pe.1000e102
   Google Scholar
• Sacristán JA, Oliva J, Campillo-Artero C, et al. ¿Qué es una intervención sanitaria eficiente en España en 2020? Gac Sanit. 2020;34:189–193. doi: 10.1016/j.gaceta.2019.06.007
   PubMed Web of Science ®Google Scholar
• Brazier J, Roberts J, Tsuchiya A, et al. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 2004;13(9):873–884. doi: 10.1002/hec.866
   PubMed Web of Science ®Google Scholar
• Horsman J, Furlong W, Feeny D, et al. The Health utilities index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1(1):54. doi: 10.1186/1477-7525-1-54
   PubMedGoogle Scholar
• Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes. 2003;1(1):4. doi: 10.1186/1477-7525-1-4
   PubMedGoogle Scholar
• Wee H-L, Machin D, Loke W-C, et al. Assessing differences in utility scores: a comparison of four widely used preference-based instruments. Value Health. 2007;10(4):256–265. doi: 10.1111/j.1524-4733.2007.00174.x
   PubMed Web of Science ®Google Scholar
• Mehl A, Goh A, Gupta S Cost-effectiveness of once-daily somatropin from Sandoz versus once-weekly somatrogon for the treatment of growth hormone deficiency in children and adolescents (EE589). ISPOR Annual Meeting; Vienna, Austria: p. 6–9 Nov 2022. Available at: https://www.ispor.org/docs/default-source/euro2022/ee589ispor-eu-2022posterandrea-mehl-pdf.pdf?sfvrsn=cf0ba714_0 (access: 21 Nov 2022).
   Google Scholar
• Rivolo S, Loftus J, Peter B, et al. Cost-effectiveness and cost-utility analysis of somatrogon once-weekly injections vs. daily growth hormone injection for treating paediatric growth hormone deficiency in Ireland. J Med Econ. 2023;26(1):963–972. doi: 10.1080/13696998.2023.2228167
   PubMed Web of Science ®Google Scholar